TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Morisky-Green Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug Attitude Inventory Scale (DAI-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Viral load kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciliary thickness parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between ciliary muscle apex and scleral spur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: formulation tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: formulation analgesic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRBC transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Appearance of grade 3 or 4 clinical or biological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of success in Partial Caries Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cortical arousals per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Local (Injection Site) Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Participant-Reported Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion Rate to Each of Four Dengue Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hospitalisation rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Agreement between highest BEC and baseline stable-state BEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects Achieving LDL-C Target Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eosinophils Per High Power Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Flow Mediated Dilation of brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of 20% of VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 20% Total FIQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reinforcing Effects of Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of lutein's antioxidant power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of inflammatory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluation of superficial effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MII Oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Survival of Capped Pulps
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants undergoing procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of randomized participants completing follow-up measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Timed Up and Go (TUG) Test Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of [18F]MNI-958
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of [18F]MNI-958
Endpoint domain: Adverse events/effects
Primary endpoint: Nominal change from baseline in percent atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nominal change from baseline in carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax (maximum drug concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost Saving
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite clinical and histological response of the Main Target Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Linkage to Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean change in best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment related >= grade 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelia Blebs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transpulmonary pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response according to IW-CLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory measurement of intact parathyroid hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Re-operations
Endpoint domain: Adverse events/effects
Primary endpoint: Level of anti-CNTO 2476 antibody in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bile leak from common bile duct
Endpoint domain: Adverse events/effects
Primary endpoint: Lens cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDSC markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of Tregs markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell/NK cell marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune checkpoint molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of S100A8/A9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HMGB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with final diagnosis of NSTE-ACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with final diagnosis of myocardial infarction at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of daily sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of XG005-03
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Changes in Organizational Support of Evidence-Based Practices
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean Changes in Organizational Commitment to Implementing Changes
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean Changes in Organizational Effectiveness in Implementing Changes
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in multifidus muscle size (cross-sectional area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in multifidus muscle fatty infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hydrogen levels in breath after lactulose ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum concentrations of progesterone, 17-Hydroxyprogesterone, LH, E2, and hCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mini-Mental State Examination total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: C-Reactive Protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: White Blood Cell (WBC) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean difference of position of the gluteal venous vasculature in relation to the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain Freedom (PF) at 2 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Most Bothersome Migraine-associated Symptom (MBS) Freedom at 2 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of all randomized patients at month 24
Endpoint domain: Mortality/survival
Primary endpoint: Changes in T-cell Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Thymus Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extracellular fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of management changes triggered by PET CT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Weight at End of Behavioural Weight Loss Program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival staining test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface disease index (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Self-Report Skin Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Self-Report Hair Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Self-Report Nail Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Endpoint of Cardiovascular Death or Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Major cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune parameters predictive of graft outcome including B cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virus replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of Signs and Symptoms of UC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of topical treatment with Imiquimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ischemic stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of hematoma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Emergency department encounter rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall Survival (OS) Time
Endpoint domain: Mortality/survival
Primary endpoint: CM exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CM Competence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: CM Sustainment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Titer (GMT) of antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxygen Saturation (rSO2) Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With PSA Best Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients achieving C-LDL goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of days with mild or no pain in the first two weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free days through day ninety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute amount of weak acids in plasma (Atot)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weak acid dissociation constant (A-)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Rating Index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of inappropriate shocks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TRL apolipoproteinB-48 production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Medio-lateral displacement during lateral inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vital signs, physical findings, and clinical laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peridialytic Arterialized Blood Bicarbonate Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peridialytic Venous Blood Bicarbonate Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peridialytic Arterialized Blood Acetate Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peridialytic Venous Blood Acetate Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cue-responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores of digestive physiological functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: scores of social psychological functions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of thyroid auto-antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cobalt Chromium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hospital anxiety and depression (HAD) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Majeed pelvic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of study drug due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants diagnosed with AKI stage 2 or 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose Limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Belinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events Considered to be at Least Possibly Related to the Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Change in peroneal nerve conduction velocity (NCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete ulcer healing at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal-failure Rate
Endpoint domain: Mortality/survival
Primary endpoint: Measured glomerular filtration rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Failure to control bleeding endoscopically
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrent bleeding after initial control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCV viral load reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concordance of hyperechogenic SN with clinical diagnosis of Parkinson's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of FDL169 (and metabolites)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration of FDL169 (and metabolites)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of FDL169 (and metabolites)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrichment of labeled pepper carotenoids in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systemic Inflammation in the Mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolome of maternal serum, umbilical cord serum and placenta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colonization in the maternal intestinal and vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower back pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hormonal classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Burke-Fahn-Marsden Dystonia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure of dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline ADHD Rating Scale-IV Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palpation tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of laboratory-confirmed influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mechanical Visual Analog Scale (mVAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean Conversion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Regression of sensory block by 2 dermatomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall survival by subtype
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline for adipokines (leptin, adiponectin and ghrelin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline for stress hormones (melatonin and cortisol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Centre of pressure path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centre of pressure velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of mutations in cancer genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Linear growth in children below 3 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: measures of learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death of any cause
Endpoint domain: Mortality/survival
Primary endpoint: revascularization (TLR, TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of blood donors testing positive for Babesia infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decreased disability in mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decreased disability in Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of placental chronic inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes